Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fighting Intensifies For China’s Hepatitis B Drug Market

This article was originally published in PharmAsia News

Executive Summary

China is the largest market for hepatitis B drugs due to the huge population at risk. Hepatitis B drugs can be classified into interferon and nucleotide products. Interferon products enjoy high brand recognition: Roche and Schering-Plough account for 52.3 percent of the hospital market, with Roche's Pegasys monopolizing 36.3 percent market share and hitting 108 percent growth in 2007. Most local firms only manage to each grab 6-7 percent of the business. For nucleotide drugs, imported and domestic products have an even fight: GSK tops the list for its lamivudine and adefovir dipivoxil, followed by Bristol-Myers Squibb and Novartis. Due to GSK's inability to get a patent for adefovir dipivoxil in China, 54 domestic organizations are applying to the State FDA for registration of products based on the drug, heating up the competition. (Click here for more - Chinese language)

You may also be interested in...



Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

In US, Market Exclusivity For NDI Notifications ‘Just Not There’ In DSHEA Regulation

Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel